MAIA BIOTECHNOLOGY INC
MAIANYSE AMERICANTrading Snapshot
- Day Range
- $1.17 – $1.22
- 52-Week Range
- $0.87 – $3.19
- Volume (shares)
- 123,668
- Avg Volume (shares)
- —
- Shares Outstanding
- 61.7M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.64
- Dividend Yield
- —
- Dilution (1yr)
- +22.8%
MAIA BIOTECHNOLOGY INC
MAIA
StockOtter · stockotter.spaceAbout MAIA BIOTECHNOLOGY INC
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
Enrollment completed in Part C of THIO-101 Phase 2 study; 65% of 2026 enrollment target reached in pivotal THIO-104 Phase 3 study
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The
MAIA: Meta Taps MongoDB CEO to Lead New Enterprise AI Platform, ft. Seth Fiegerman | Open Interest
Seth Fiegerman says Meta is moving aggressively into AI agents, with a new enterprise product that looks like a ‘Muse'-style assistant for workplace use. He notes that the company's push suggests the focus is shifting fr
MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
THIO-104 advances toward key 2027 interim survival analysis CHICAGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company f
MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer
Strong pace of patient enrollment supports continued advancement toward regulatory milestones Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control ra
MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial
Milestone follows FDA clearance of MAIA's amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies